



RECOMMENDATIONS FOR THE COMPOSITION OF INFLUENZA VACCINES IN 2023 FOR THE SOUTHERN HEMISPHERE*

The World Health Organization (WHO) has released its recommendations for the composition of influenza vaccines for the southern hemisphere influenza season in 2023. These recommendations are based on data collected by the WHO Global Influenza Surveillance and Response System (GISRS), a network of over 150 laboratories in 127 countries that conducts year-round surveillance of influenza and other respiratory viruses.

The periodic update of viral strains included in influenza vaccines is necessary to ensure their effectiveness, as influenza viruses are constantly evolving. These recommendations will be used by national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the upcoming season.

According to WHO, around one billion people get seasonal influenza every year, and the threat of an influenza pandemic is always present. Therefore, monitoring circulating respiratory viruses, including influenza, is critical to inform vaccine composition recommendations, which WHO issues twice a year. For the 2023 southern hemisphere influenza season, WHO recommends

that quadrivalent vaccines contain the following:

Egg-based vaccines:

- an A/Sydney/5/2021 (H1N1) pdm09-Like virus;
- an A/Darwin/9/2021 (H3N2)-Like virus;
- a B/Austria/1359417/2021 (B/Victoria Lineage)-Like virus; and
- a B/Phuket/307 3/2013 (B/Yamagata Lineage)-Like virus.

Read the full article and other vaccine compositions recommended by WHO link given in the reference section.

FluQuadri® is an inactivated quadrivalent inactivated influenza vaccine (SPLIT VIRION) I.P. SH- 2023. FluQuadri® is indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine.

Each dose of 0.5ml contains:

A/Sydney/5/2021 (H1N1) pdm09 - like strain.....15 mcg hemagglutinin
 A/Darwin/9/2021 (H3N2) - like strain).....15 mcg hemagglutinin
 B/Austria/1359417/2021- (B/Victoria lineage)- like strain.15 mcg hemagglutinin
 B/Phuket/3073/2013- (B/Yamagata lineage)- like strain..15 mcg hemagglutinin

with other inactive ingredients

Age	Dose	Schedule
6 months through 35 months	One or two doses ^a , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
36 months through 8 years	One or two doses ^a , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
9 years and older	One dose, 0.5ml	-


a 1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.

(Please refer to PI on www.Sanofi.in if more information is required)

For the use of Registered Medical Practitioner only

sanofi


When Risk of Influenza is at its Peak, what one needs is Peak Protection



FluQuadri[®]

Quadrivalent Inactivated Influenza Vaccine (Split Virion) I.P.

From the world leader in influenza vaccine*



STOP FLU
with
P.E.A.K.
PROTECTION


**With Latest WHO Recommended
SH 2023 Flu Vaccine Strains Composition¹**

Indicated for all
persons **6 months**
of age and older²

Demonstrated Robust
Seroprotection against
**H1N1, H3N2, and
B Strains**^{2,3}

**Split Virion Vaccine
advantage** with more than
8 fold Increase in HAI Titres
post Vaccination in
Indian Children^{2,4}

Provides Assurance of
Quality as **FLUQUADRI**[®]
is **India's 1st** and **only**
WHO prequalified
Quadrivalent Inactivated
Flu Vaccine⁵



**Please call your distributor or
Sanofi personnel to place order Today**

Click Here

For More Product Information Click Here
*Based on the global market share of Sanofi's influenza vaccines. Source: Statista (2022).
1. WHO Weekly Epidemiol. Rec. Influenza Circulation Report (2022) 47(1).
2. WHO Weekly Epidemiol. Rec. Influenza Circulation Report (2022) 47(1).
3. WHO Weekly Epidemiol. Rec. Influenza Circulation Report (2022) 47(1).
4. WHO Weekly Epidemiol. Rec. Influenza Circulation Report (2022) 47(1).
5. WHO Weekly Epidemiol. Rec. Influenza Circulation Report (2022) 47(1).

sanofi | Sanofi Healthcare India Pvt. Ltd.
Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai - 400072, India.

Read the full article and other vaccine compositions recommended by WHO in the link below-

<https://www.who.int/news/item/23-09-2022-new-recommendations-for-the-composition-of-influenza-vaccines-in-2023-for-the-southern-hemisphere>

Reference: *New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere
<https://www.who.int/news/item/23-09-2022-new-recommendations-for-the-composition-of-influenza-vaccines-in-2023-for-the-southern-hemisphere> accessed on 18-04-2023

For full prescribing information visit - <https://app.hidoc.co/5A87F1>

sanofi

Sanofi Healthcare India (P) Ltd.

Sanofi House CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072,
Tel No. 022-28032000, Fax: 022-28032939